tiprankstipranks
Outlook Therapeutics (DE:41O)
FRANKFURT:41O
Germany Market
41O
Outlook Therapeutics
RESEARCH TOOLSreports

Outlook Therapeutics (41O) Income Statement

7 Followers

Outlook Therapeutics Income Statement

Last quarter (Q3 2026), Outlook Therapeutics's total revenue was $9.00K, a decrease of -99.40% from the same quarter last year. In Q3, Outlook Therapeutics's net income was $-20.32M. See Outlook Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Sep 25Sep 24Sep 23Sep 22Sep 21
Total Revenue
$ 1.41M$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 657.21K$ 0.00$ 0.00$ -204.69K$ 0.00
Operating Expenses
$ 67.72M$ 71.70M$ 53.13M$ 62.87M$ 51.73M
Depreciation and Amortization
$ 117.05K$ 113.86K$ 44.19K$ 204.69K$ 262.14K
EBITDA
$ -63.58M$ -72.09M$ -56.40M$ -64.36M$ -51.96M
Operating Income
$ -67.06M$ -71.70M$ -53.13M$ -63.07M$ -51.73M
Other Income/Expenses
$ 3.08M$ -3.66M$ -5.85M$ -2.98M$ -1.43M
Pretax Income
$ -63.98M$ -75.36M$ -58.98M$ -66.05M$ -53.16M
Net Income
$ -62.42M$ -75.37M$ -58.98M$ -66.05M$ -53.16M
Per Share Metrics
Basic EPS
$ -1.79$ -4.06$ -4.80$ -6.23$ -7.00
Diluted EPS
$ -1.79$ -4.06$ -4.80$ -6.23$ -7.00
Weighted Average Shares Outstanding
 25.48M 18.55M 12.51M 10.60M 7.63M
Weighted Average Shares Outstanding (Diluted)
 25.48M 18.55M 12.51M 10.60M 7.63M
Currency in USD

Outlook Therapeutics Earnings and Revenue History